Metamizole is a powerful analgesic drug whose varying regulatory status from country to country reflects its mixed benefit-risk profile. Patients must be instructed about the risk of agranulocytosis and the symptoms by which it can be recognized early.
Cascorbi et al. (Fri,) studied this question.